| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Oncotelic Therapeutics, Inc. | Director | Common Stock | 3.33M | $86.6K | $0.03 | 31 Mar 2021 | By Artius Bioconsulting |
| Oncotelic Therapeutics, Inc. | Director | Stock Options | 500K | 03 Sep 2021 | Direct | ||
| Oncotelic Therapeutics, Inc. | Director | Series A Convertible Preferred Stock | 0 | 31 Mar 2021 | By Artius Bioconsulting | ||
| Mosaic ImmunoEngineering Inc. | President and CEO, Director, 10%+ Owner | Convertible Note | $20K | 18 Feb 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CPMV | Mosaic ImmunoEngineering Inc. | 18 Feb 2022 | 1 | $20K | 4 | President and CEO, Director, 10%+ Owner | 22 Feb 2022, 19:01 |
| OTLC | Oncotelic Therapeutics, Inc. | 03 Sep 2021 | 1 | $0 | 4 | Director | 08 Sep 2021, 17:00 |
| OTLC | Oncotelic Therapeutics, Inc. | 31 Mar 2021 | 3 | $0 | 4 | Director | 16 Jul 2021, 17:37 |